Most of the focus at Almirall SA is on securing EU approval for the closely watched atopic dermatitis drug lebrikizumab but the Spanish drugmaker is also looking to bring in other assets to feed the pipeline.
As part of that strategy, Almirall has closed a €200m capital raise through the issue of around 24.4 million new...








